GlaxoSmithKline plc (GSK) – Britain has taken arms in an effort to provide a vaccine against meningitis to all babies. Britain will be the first county to do this after reaching a price agreement with GlaxoSmithKline plc (GSK).
The move has come after the government advisors suggested this approach. They recommended the Bexsero vaccine a year ago. A lot of time has been spent since then, trying to negotiate the cost of this drug.
Novartis AG (NVS) had previous ownership of the drug, which was then passed over to GlaxoSmithKline during the sale of Novartis’s vaccine business.
The move has been carried out with a lot of pride by the British Government. Jeremy Hunt who is the Health Secretary expressed his happiness with this achievement with Britain becoming the first country in the world to introduce a vaccine against meningitis B.
The health program will introduce the vaccination to babies at the tender age of two years. Additionally there will be other supplemental dosages to follow up.
The vaccine is expected to be very effective towards combating the meningitis which is a bacterial infection. The infection usually attacks the lining of the brain as well as the spinal cord. It is common in teenagers and infants.
The agreement with GlaxoSmithKline will see the vaccination process initiated into the National Health Service within this year. The project has also captured the attention of other countries. Scotland and Wales are also looking to get into the deal, with negotiations to secure vaccination for their countries already on the way.
The project is expected to improve the health situation and provide the children with a brighter future, free the infirmity. Other governments worldwide are expected to adopt the new strategy in the near future, so as to join in the fight against the disease. This will impact great change within the medical docket.
With GlaxoSmithKline cashing in on the lucrative deal, future research is expected to be carried out on other threatening diseases.